Prostate Cancer Coverage from Every Angle

Michael S. Hofman, MBBS, on LuPSMA vs Cabazitaxel: Clinical Implications of the ANZUP 1603 Prostate Cancer Trial

Posted: Sunday, May 31, 2020

Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses LuPSMA as a more active agent than cabazitaxel in men with docetaxel-treated metastatic castration-resistant prostate cancer, differences in these treatment approaches, and whether supportive measures were needed for toxicities in the investigational drug.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.